AU1896295A - Recombinant adenoviruses coding for brain-derived neurotrophic factor (bdnf) - Google Patents

Recombinant adenoviruses coding for brain-derived neurotrophic factor (bdnf)

Info

Publication number
AU1896295A
AU1896295A AU18962/95A AU1896295A AU1896295A AU 1896295 A AU1896295 A AU 1896295A AU 18962/95 A AU18962/95 A AU 18962/95A AU 1896295 A AU1896295 A AU 1896295A AU 1896295 A AU1896295 A AU 1896295A
Authority
AU
Australia
Prior art keywords
bdnf
brain
neurotrophic factor
derived neurotrophic
recombinant adenoviruses
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU18962/95A
Other versions
AU703793B2 (en
Inventor
Pascal Barneoud
Pia Delaere
Michel Perricaudet
Laurent Pradier
Emmanuelle Vigne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU1896295A publication Critical patent/AU1896295A/en
Application granted granted Critical
Publication of AU703793B2 publication Critical patent/AU703793B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU18962/95A 1994-03-18 1995-03-02 Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF) Ceased AU703793B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9403191 1994-03-18
FR9403191A FR2717496B1 (en) 1994-03-18 1994-03-18 Recombinant viruses, preparation and use in gene therapy.
PCT/FR1995/000250 WO1995025804A1 (en) 1994-03-18 1995-03-02 Recombinant adenoviruses coding for brain-derived neurotrophic factor (bdnf)

Publications (2)

Publication Number Publication Date
AU1896295A true AU1896295A (en) 1995-10-09
AU703793B2 AU703793B2 (en) 1999-04-01

Family

ID=9461190

Family Applications (1)

Application Number Title Priority Date Filing Date
AU18962/95A Ceased AU703793B2 (en) 1994-03-18 1995-03-02 Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)

Country Status (12)

Country Link
EP (1) EP0750676A1 (en)
JP (1) JPH09510358A (en)
KR (1) KR970701784A (en)
AU (1) AU703793B2 (en)
CA (1) CA2184200A1 (en)
FI (1) FI963674A (en)
FR (1) FR2717496B1 (en)
IL (1) IL112992A0 (en)
MX (1) MX9603490A (en)
NO (1) NO963559L (en)
WO (1) WO1995025804A1 (en)
ZA (1) ZA952244B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740641B2 (en) * 1996-09-13 2001-11-08 Aventis Pharma S.A. Method for treating amyotrophic lateral sclerosis

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
CA2408255A1 (en) * 2000-05-05 2001-11-15 Marie T. Filbin Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
EP3755380A4 (en) * 2018-02-20 2021-12-08 Carmel-Haifa University Economic Corporation Ltd. Compositions and methods for delivery and expression of small inhibitory peptides and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113083A1 (en) * 1991-07-10 1993-01-21 Vivien Wong Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules
AU3129793A (en) * 1991-11-08 1993-06-07 General Hospital Corporation, The Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
FR2688514A1 (en) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
EP0669987B1 (en) * 1992-09-25 2008-08-13 Aventis Pharma S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
FR2704234B1 (en) * 1993-04-22 1995-07-21 Centre Nat Rech Scient RECOMBINANT VIRUSES, PREPARATION AND USE IN GENE THERAPY.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU740641B2 (en) * 1996-09-13 2001-11-08 Aventis Pharma S.A. Method for treating amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
AU703793B2 (en) 1999-04-01
MX9603490A (en) 1997-03-29
KR970701784A (en) 1997-04-12
EP0750676A1 (en) 1997-01-02
ZA952244B (en) 1996-01-16
JPH09510358A (en) 1997-10-21
FR2717496B1 (en) 1996-04-12
FI963674A0 (en) 1996-09-17
IL112992A0 (en) 1995-06-29
WO1995025804A1 (en) 1995-09-28
NO963559L (en) 1996-08-26
CA2184200A1 (en) 1995-09-28
FR2717496A1 (en) 1995-09-22
FI963674A (en) 1996-09-17

Similar Documents

Publication Publication Date Title
IL116816A0 (en) Recombinant defective adenoviruses
AU3447097A (en) Method for producing recombinant adenovirus
AU2639095A (en) Recombinant hk2 polypeptide
AU3547095A (en) Luminance control film
AU4370596A (en) Novel hedgehog-derived polypeptides
AU2380895A (en) Vasoactive intestinal polypeptide
AU2142595A (en) Recombinant adenoviruses coding for basic fibroblast growth factors (bfgf)
AU4935996A (en) Lan bridging redundancy
AU2672397A (en) AL-2 neurotrophic factor
AUPN765396A0 (en) Crypt system
AU5109796A (en) Export systems for recombinant proteins
AU3733497A (en) Recombinant sef14 fimbrial protein from salmonella
AU2677797A (en) Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor
AU2384195A (en) Camber control sail system
AU1896295A (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (bdnf)
AU2075899A (en) Neurotrophic factor secretion promoters
AU1896195A (en) Recombinant adenoviruses coding for acidic fibroblast growth factor (afgf)
AU2010592A (en) Neurotrophic factor, preparation and uses thereof
AU4692396A (en) Anti-inflammatory cd14 polypeptides
AU3398797A (en) Polynucleotides encoding secreted proteins
AU1282895A (en) Novel human ciliary neurotrophic factor
AU7165998A (en) Neurotrophic factor receptors
AU5597998A (en) Recombinant plague vaccine
AU3734693A (en) Neurotrophic peptides
AU628500B2 (en) Neurotrophic peptides